ClinicalTrials.gg
CompletedNCT05736393Updated Sep 30, 2026Results posted

Translation of Robotic Apparel for Alleviating Low Back Pain

An interventional study of Back Exosuit in Low Back Pain, sponsored by Boston University Charles River Campus. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
415th of 623
44 · median 79
Started
2024
with 31 others
No phase
408 of 712
62 open now
Registered
578th of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 415th largest by enrollment of the 623 interventional ones that give a count, is one of 32 that started in 2024, is one of 408 with no phase, and was the 578th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

This is a NIAMS-sponsored clinical trial being conducted through the NIH Helping to End Addition Long-term (HEAL) Initiative's Back Pain Consortium (BACPAC) Research Program. This is a single-arm controlled trial with individuals aged 18-70 with low back pain (LBP). This study investigates the effect(s) of augmenting physical therapy (PT) interventions with the use of an experimental wearable soft robotic device ('exosuit').

Read the detailed description

Low back pain (LBP) has a lifetime prevalence of 80%, with approximately 20% of individuals experiencing recurrent episodes or chronic LBP (cLBP). Unfortunately, the evidence for the effectiveness of most rehabilitative treatment is low. With an economic burden approaching $100-billion in the United States alone, the National Institutes of Health has invested millions of dollars in innovative technologies aiming to improve rehabilitative care for low back injuries. As part of this initiative, the investigator's collaborative network of expert clinicians, engineers, and researchers have developed and tested robotic apparel technology (exosuit) that supplements ergonomic and biomechanical training and can be utilized by clinicians in the treatment of individuals with LBP.

Failed rehabilitation, and thus progression from acute to cLBP, is thought to be caused by maladaptive motor control strategies, muscle hyperactivity, reduced movement variability, and development of fear-avoidance-beliefs. The exosuit technology was designed to reduce exertion, encourage safe, varied movement strategies, and promote recovery through well-timed assistive forces to the trunk and hips during flexion postures and lifting tasks. The proposed project builds on this work through use of the exosuit to augment traditional physical therapy care. In doing so, the investigators will determine whether this technology can enhance rehabilitation after back injuries, interrupt the progression of acute to chronic LBP, encourage non-maladaptive movement strategies, and expedite the timeline of return to prior level of function.

To examine the effects of exosuit augmented physical therapy rehabilitation and reduce disability, the investigators will recruit individuals with LBP who are referred to or receiving physical therapy into a single arm clinical trial. The investigators will evaluate feasibility, safety and usability of the exosuit, as well as changes in pain and disability throughout 6 weeks of rehabilitation and compare outcomes to a historical control group who received usual care. The investigators will also evaluate changes in fear-avoidance beliefs, range of motion, and motor control and compare outcomes between exosuit-augmented and no suit conditions over the 6 weeks. Primary outcomes of feasibility, usability, and safety of using a back exosuit to augment routine physical therapy will be evaluated. Secondary outcomes include the efficacy of using a back exosuit to augment routine physical therapy, measured by comparing changes in self-perceived pain and disability compared to the historical control group. Tertiary outcomes include the identification of interventional phenotypes by determining the relationship between changes in symptoms and changes in biomechanics function through exosuit-augmented physical therapy.

03

Conditions studied

  • Low Back Pain

Keywords

  • Low Back Pain
  • Chronic Pain
  • Rehabilitation
  • Exosuit
  • Clinical Trial
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70
  • Diagnosis of LBP by licensed medical provider or self-report of lower back pain (initially gathered through partial HIPAA waiver, and confirmed during in-person screening visit)
  • Self-reported LBP with bending or lifting
  • Able to walk without an assistive device.
  • Willing and able to provide .
  • Provide HIPAA Authorization to allow communication with the primary healthcare provider (e.g., treating physical therapist) for communication (as needed) during the study period.
  • Must undergo physical therapy examination with research physical therapist and be assigned a Treatment-Based Classification (TBC) of movement impairment or control impairment.

Exclusion criteria

Exclusion Criteria:

  • Unable to attend all scheduled visits and 1-month phone follow-up
  • Currently pregnant or likely to become pregnant within 6 weeks
  • Having received surgery to address current LBP
  • Having pain or symptoms below the knee that seems related to their current LBP
  • Having current LBP lasting less than 2 weeks
  • Diagnosed or self-reported neurological disorders effecting motor control (stroke, Parkinson's disease, etc.)
  • Use of a pacemaker or other implanted medical devices
  • Currently under treatment for cancer
  • Skin issues / sensitivity that an exosuit could exacerbate (e.g., Epidermolysis Bullosa)
  • Any other medical conditions that would preclude safe use of the exosuit device as determined by a physical therapist
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Exosuit Augmented Physical Therapy

    Participants will attend an in person screening, initial visit (1), 10 (2-11) sessions of physical therapy and a discharge visit (12). Participants will undergo a comprehensive biomechanical analysis on visits 1, 3, 6, 9 and 12, completing an extensive battery of surveys at visits 1, discharge, and 1-month post-discharge. Treatment will incorporate evidence-based physical therapy care based on clinical presentation to include manual therapy, therapeutic exercise, and functional therapeutic activities. A portion of each session will include exosuit use.

    Device: Back Exosuit

Interventions

  • DeviceBack Exosuit

    The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.

06

What researchers measure

Primary outcomes

  1. Suit Usability Measured by Quebec User Evaluation of Satisfaction With Assistive Technology (QUEST Survey 2.0)

    Suit usability measured by the QUEST survey 2.0. The QUEST is a standardized usability scale to determine a user's device satisfaction. Results range from 1 to 5 on a Likert Scale, with higher scores (5) corresponding to a very satisfied response.

    Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.

  2. Suit Safety Measured by Patient-reported Pain

    The Numerical Rating Scale of Pain will measure patient-reported levels of current pain intensity at the beginning and end of every study visit. Results range from 0 to 10, with higher scores indicating increased pain intensity.

    Time frame: Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment)

  3. Suit Effect & Safety Measured by Perceived Task Discomfort

    The patient-reported level of task discomfort will be measured at the end of selected biomechanical assessment tasks (performed with the suit in a slack and active condition). Participants will rank task discomfort on a numerical rating scale of task discomfort. Results range from 0 to 10, with higher scores indicating higher total body difficulty.

    Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.

  4. Suit Effect Measured by Concern of Movement

    Patient-reported level of concern of movement will be measured at the end of each biomechanical visit. Four selected images from the Photo Series of Daily Activity will be ranked, with the participants envisioning themselves completing the task with or without the aid of the exosuit (Quirk et al., 2023). Results range from 0 to 10, with higher scores indicating higher concern with completing the task.

    Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.

  5. Suit Effect Measured by Perceived Task Effort

    Patient-reported level of task effort will be measured at the end of selected biomechanical assessment tasks (performed with the suit in a slack and active condition). Participants will rank task difficulty on a numerical rating scale of task difficulty. Results range from 0 to 10, with higher scores indicating higher task difficulty.

    Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.

  6. Functional Suit Effect Measured by Peak Deadlift Pull Force

    Measured during maximum voluntary isometric contractions pounds will be measured using a stationary dynamometer. Peak full force will be measured for the slack and active suit condition.

    Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.

  7. Failure Percentage Level 6

    For this progressive lifting test starting in a randomized active or slack condition women and men would start from level 1 lifting a 8 or 13 pound weighted tote off of the floor and unto a 75cm high table with the goal to complete 4 repetitions within 20 seconds. If the participants were successful (pass) they would advance to the next level adding 5 pounds to the tote, however if they were unwilling or failed a level the task would end. The task advanced to a maximum of 6 levels corresponding to a 33 and 38 pound mass for women and men respectively. The following outcome identifies the % of participants who failed the task at or before level 6 in their slack and active condition.

    Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.

  8. Functional Suit Effect Measured by Endurance Lifting Task

    Measured during dynamic 2.5 minute dynamic asymmetric lifting task. The maximum number of continuous repetitions (rep) performed will compared between the slack and active suit conditions.

    Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.

Secondary outcomes

  1. Pain Measured by Numerical Rating Scale of Pain (Worst in Last 24 Hours)

    Patient-reported level of their worse pain intensity in the last 24 hours will be measured by the Numerical Rating Scale of Pain, at the beginning of every study visit. Results range from 0 to 10, with higher scores indicating increased pain intensity.

    Time frame: Pre Every Visit including baseline (time 0), all follow-up visits

  2. Patient-reported Disability Score Measured by the Modified Oswestry Disability Questionnaire (MDQ)

    Patient-reported pain intensity and interference is measured by the Modified Oswestry Disability Questionnaire (MDQ) scale. The MDQ is a series of 10 questions. Results range from 0 to 50, with higher scores indicating increased low-back related disability.

    Time frame: Pre Every Visit including baseline (time 0)

07

Results

Posted Sep 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneExosuit Augmented Physical Therapy
Started44
Completed39
Not completed5
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2
Withdrew: Lack of time1
Withdrew: Moved1

Outcome measures

PrimarySuit Usability Measured by Quebec User Evaluation of Satisfaction With Assistive Technology (QUEST Survey 2.0)

Suit usability measured by the QUEST survey 2.0. The QUEST is a standardized usability scale to determine a user's device satisfaction. Results range from 1 to 5 on a Likert Scale, with higher scores (5) corresponding to a very satisfied response.

Time frame:
Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Reported as:
Mean · units on a scale
Suit Usability Measured by Quebec User Evaluation of Satisfaction With Assistive Technology (QUEST Survey 2.0)
units on a scaleExosuit Augmented Physical Therapy
Visit 14.2 ± 0.7
Visit 34.3 ± 0.6
Visit 64.4 ± 0.7
Visit 94.4 ± 0.6
Visit 124.4 ± 0.6
PrimarySuit Safety Measured by Patient-reported Pain

The Numerical Rating Scale of Pain will measure patient-reported levels of current pain intensity at the beginning and end of every study visit. Results range from 0 to 10, with higher scores indicating increased pain intensity.

Time frame:
Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment)
Reported as:
Mean · units on a scale
Suit Safety Measured by Patient-reported Pain
units on a scaleStart of Visit for Exosuit Augmented Physical TherapyEnd of Visit for Exosuit Augmented Physical Therapy
Visit 12.4 ± 1.53.7 ± 2.2
Visit 32.2 ± 1.63.0 ± 1.5
Visit 62.1 ± 1.83.4 ± 1.9
Visit 91.5 ± 1.12.4 ± 1.7
Visit 121.5 ± 1.42.6 ± 2.2
PrimarySuit Effect & Safety Measured by Perceived Task Discomfort

The patient-reported level of task discomfort will be measured at the end of selected biomechanical assessment tasks (performed with the suit in a slack and active condition). Participants will rank task discomfort on a numerical rating scale of task discomfort. Results range from 0 to 10, with higher scores indicating higher total body difficulty.

Time frame:
Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Reported as:
Mean · units on a scale
Suit Effect & Safety Measured by Perceived Task Discomfort
units on a scaleExosuit Augmented Physical Therapy- ActiveExosuit Augmented Physical Therapy- Slack
Visit 14.6 ± 2.35.2 ± 2.4
Visit 33.9 ± 1.74.2 ± 1.8
Visit 64.0 ± 1.84.2 ± 1.8
Visit 93.5 ± 1.83.9 ± 1.7
Visit 123.7 ± 2.23.8 ± 2.2
PrimarySuit Effect Measured by Concern of Movement

Patient-reported level of concern of movement will be measured at the end of each biomechanical visit. Four selected images from the Photo Series of Daily Activity will be ranked, with the participants envisioning themselves completing the task with or without the aid of the exosuit (Quirk et al., 2023). Results range from 0 to 10, with higher scores indicating higher concern with completing the task.

Time frame:
Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Reported as:
Mean · units on a scale
Suit Effect Measured by Concern of Movement
units on a scaleExosuit Augmented Physical Therapy for Shovel ActiveExosuit Augmented Physical Therapy for Shovel Stack
Visit 13.5 ± 2.15.2 ± 2.5
Visit 33.1 ± 2.44.7 ± 2.6
Visit 62.9 ± 2.34.3 ± 2.3
Visit 92.7 ± 2.44.4 ± 2.7
Visit 122.6 ± 2.14.1 ± 2.1
PrimarySuit Effect Measured by Perceived Task Effort

Patient-reported level of task effort will be measured at the end of selected biomechanical assessment tasks (performed with the suit in a slack and active condition). Participants will rank task difficulty on a numerical rating scale of task difficulty. Results range from 0 to 10, with higher scores indicating higher task difficulty.

Time frame:
Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Reported as:
Mean · units on a scale
Suit Effect Measured by Perceived Task Effort
units on a scaleExosuit Augmented Physical Therapy Active EffortExosuit Augmented Physical Therapy Slack Effort
Visit 16.2 ± 1.96.8 ± 1.6
Visit 35.6 ± 2.06.1 ± 2.1
Visit 65.3 ± 1.76.1 ± 2.0
Visit 95.4 ± 2.36.0 ± 2.0
Visit 125.4 ± 2.35.6 ± 2.1
PrimaryFunctional Suit Effect Measured by Peak Deadlift Pull Force

Measured during maximum voluntary isometric contractions pounds will be measured using a stationary dynamometer. Peak full force will be measured for the slack and active suit condition.

Time frame:
Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Reported as:
Mean · pounds
Functional Suit Effect Measured by Peak Deadlift Pull Force
poundsExosuit Augmented Physical Therapy Pull Force ActiveExosuit Augmented Physical Therapy Pull Force Slack
Visit 1191.9 ± 74.2184.3 ± 73.5
Visit 3198.3 ± 81.4193.7 ± 93.2
Visit 6204.0 ± 85.6201.5 ± 87.2
Visit 9216.7 ± 94.6215.0 ± 96.
Visit 12206.8 ± 90.6200.3 ± 91.5
PrimaryFailure Percentage Level 6

For this progressive lifting test starting in a randomized active or slack condition women and men would start from level 1 lifting a 8 or 13 pound weighted tote off of the floor and unto a 75cm high table with the goal to complete 4 repetitions within 20 seconds. If the participants were successful (pass) they would advance to the next level adding 5 pounds to the tote, however if they were unwilling or failed a level the task would end. The task advanced to a maximum of 6 levels corresponding to a 33 and 38 pound mass for women and men respectively. The following outcome identifies the % of participants who failed the task at or before level 6 in their slack and active condition.

Time frame:
Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Reported as:
Count of participants · Participants
Failure Percentage Level 6
ParticipantsExosuit Augmented Physical Therapy ActiveExosuit Augmented Physical Therapy Active Slack
Visit 169
Visit 378
Visit 656
Visit 933
Visit 1223
PrimaryFunctional Suit Effect Measured by Endurance Lifting Task

Measured during dynamic 2.5 minute dynamic asymmetric lifting task. The maximum number of continuous repetitions (rep) performed will compared between the slack and active suit conditions.

Time frame:
Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Reported as:
Mean · number of repetitions
Functional Suit Effect Measured by Endurance Lifting Task
number of repetitionsExosuit Augmented Physical Therapy Continuous Reps ActiveExosuit Augmented Physical Therapy Continuous Reps Slack
Visit 133.7 ± 18.328.1 ± 20.4
Visit 334.7 ± 23.532.0 ± 21.2
Visit 634.7 ± 18.929.9 ± 20.5
Visit 940.5 ± 25.334.8 ± 26.1
Visit 1243.4 ± 26.436.7 ± 22.4
SecondaryPain Measured by Numerical Rating Scale of Pain (Worst in Last 24 Hours)

Patient-reported level of their worse pain intensity in the last 24 hours will be measured by the Numerical Rating Scale of Pain, at the beginning of every study visit. Results range from 0 to 10, with higher scores indicating increased pain intensity.

Time frame:
Pre Every Visit including baseline (time 0), all follow-up visits
Reported as:
Mean · score on a scale
Pain Measured by Numerical Rating Scale of Pain (Worst in Last 24 Hours)
score on a scaleExosuit Augmented Physical Therapy
Visit 12.7 ± 1.6
Visit 22.5 ± 1.7
Visit 32.4 ± 1.6
Visit 42.4 ± 1.8
Visit 51.8 ± 1.7
Visit 62.2 ± 1.7
Visit 71.9 ± 1.7
Visit 81.6 ± 1.3
Visit 91.6 ± 1.2
Visit 101.2 ± 1.0
Visit 111.5 ± 1.1
Visit 120.8 ± 1.0
SecondaryPatient-reported Disability Score Measured by the Modified Oswestry Disability Questionnaire (MDQ)

Patient-reported pain intensity and interference is measured by the Modified Oswestry Disability Questionnaire (MDQ) scale. The MDQ is a series of 10 questions. Results range from 0 to 50, with higher scores indicating increased low-back related disability.

Time frame:
Pre Every Visit including baseline (time 0)
Reported as:
Mean · score on a scale
Patient-reported Disability Score Measured by the Modified Oswestry Disability Questionnaire (MDQ)
score on a scaleExosuit Augmented Physical Therapy
Visit 115.8 ± 11.7
Visit 214.8 ± 10.3
Visit 313.0 ± 9.5
Visit 413.2 ± 9.9
Visit 510.9 ± 9.3
Visit 611.8 ± 9.8
Visit 710.9 ± 9.0
Visit 89.4 ± 9.0
Visit 98.9 ± 9.4
Visit 108.6 ± 9.0
Visit 117.1 ± 7.4
Visit 127.1 ± 5.2

Adverse events

Collected over 6-8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exosuit Augmented Physical Therapy0/44 (0%)0/44 (0%)4/44 (9.1%)
Most frequent other events
Most frequent other events
EventExosuit Augmented Physical Therapy
Increased lower back painMusculoskeletal and connective tissue disorders4/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)Exosuit Augmented Physical Therapy
Mean31.7 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Exosuit Augmented Physical Therapy
Female20
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Exosuit Augmented Physical Therapy
Hispanic or Latino6
Not Hispanic or Latino38
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Exosuit Augmented Physical Therapy
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American4
White27
More than one race3
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Exosuit Augmented Physical Therapy
United States44
08

Study locations

1 site
  • Boston University Physical Therapy Center
    Boston, Massachusetts 02215, United States
09

References and documents

Publications

  • Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, Williams G, Smith E, Vos T, Barendregt J, Murray C, Burstein R, Buchbinder R. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014 Jun;73(6):968-74. doi: 10.1136/annrheumdis-2013-204428. Epub 2014 Mar 24. PubMed 24665116 ↗
  • Rubin DI. Epidemiology and risk factors for spine pain. Neurol Clin. 2007 May;25(2):353-71. doi: 10.1016/j.ncl.2007.01.004. PubMed 17445733 ↗
  • Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, Horst C, Kaldjian A, Matyasz T, Scott KW, Bui AL, Campbell M, Duber HC, Dunn AC, Flaxman AD, Fitzmaurice C, Naghavi M, Sadat N, Shieh P, Squires E, Yeung K, Murray CJL. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA. 2020 Mar 3;323(9):863-884. doi: 10.1001/jama.2020.0734. PubMed 32125402 ↗
  • Balague F, Mannion AF, Pellise F, Cedraschi C. Non-specific low back pain. Lancet. 2012 Feb 4;379(9814):482-91. doi: 10.1016/S0140-6736(11)60610-7. Epub 2011 Oct 6. PubMed 21982256 ↗
  • Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017 Feb 18;389(10070):736-747. doi: 10.1016/S0140-6736(16)30970-9. Epub 2016 Oct 11. PubMed 27745712 ↗
  • Chou R, Shekelle P. Will this patient develop persistent disabling low back pain? JAMA. 2010 Apr 7;303(13):1295-302. doi: 10.1001/jama.2010.344. PubMed 20371789 ↗
  • Vlaeyen JWS, Linton SJ. Fear-avoidance model of chronic musculoskeletal pain: 12 years on. Pain. 2012 Jun;153(6):1144-1147. doi: 10.1016/j.pain.2011.12.009. Epub 2012 Feb 8. No abstract available. PubMed 22321917 ↗
  • Leeuw M, Goossens ME, Linton SJ, Crombez G, Boersma K, Vlaeyen JW. The fear-avoidance model of musculoskeletal pain: current state of scientific evidence. J Behav Med. 2007 Feb;30(1):77-94. doi: 10.1007/s10865-006-9085-0. Epub 2006 Dec 20. PubMed 17180640 ↗
  • Christe G, Crombez G, Edd S, Opsommer E, Jolles BM, Favre J. Relationship between psychological factors and spinal motor behaviour in low back pain: a systematic review and meta-analysis. Pain. 2021 Mar 1;162(3):672-686. doi: 10.1097/j.pain.0000000000002065. PubMed 33591109 ↗
  • Wertli MM, Rasmussen-Barr E, Weiser S, Bachmann LM, Brunner F. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review. Spine J. 2014 May 1;14(5):816-36.e4. doi: 10.1016/j.spinee.2013.09.036. Epub 2013 Oct 18. PubMed 24412032 ↗
  • Johansson H, Sojka P. Pathophysiological mechanisms involved in genesis and spread of muscular tension in occupational muscle pain and in chronic musculoskeletal pain syndromes: a hypothesis. Med Hypotheses. 1991 Jul;35(3):196-203. doi: 10.1016/0306-9877(91)90233-o. PubMed 1943863 ↗
  • van Dieen JH, Reeves NP, Kawchuk G, van Dillen LR, Hodges PW. Motor Control Changes in Low Back Pain: Divergence in Presentations and Mechanisms. J Orthop Sports Phys Ther. 2019 Jun;49(6):370-379. doi: 10.2519/jospt.2019.7917. Epub 2018 Jun 12. PubMed 29895230 ↗
  • George SZ, Fritz JM, Silfies SP, Schneider MJ, Beneciuk JM, Lentz TA, Gilliam JR, Hendren S, Norman KS. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021. J Orthop Sports Phys Ther. 2021 Nov;51(11):CPG1-CPG60. doi: 10.2519/jospt.2021.0304. PubMed 34719942 ↗
  • Alrwaily M, Timko M, Schneider M, Stevans J, Bise C, Hariharan K, Delitto A. Treatment-Based Classification System for Low Back Pain: Revision and Update. Phys Ther. 2016 Jul;96(7):1057-66. doi: 10.2522/ptj.20150345. Epub 2015 Dec 4. PubMed 26637653 ↗
  • van Middelkoop M, Rubinstein SM, Kuijpers T, Verhagen AP, Ostelo R, Koes BW, van Tulder MW. A systematic review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. Eur Spine J. 2011 Jan;20(1):19-39. doi: 10.1007/s00586-010-1518-3. Epub 2010 Jul 18. PubMed 20640863 ↗
  • Tagliaferri SD, Mitchell UH, Saueressig T, Owen PJ, Miller CT, Belavy DL. Classification Approaches for Treating Low Back Pain Have Small Effects That Are Not Clinically Meaningful: A Systematic Review With Meta-analysis. J Orthop Sports Phys Ther. 2022 Feb;52(2):67-84. doi: 10.2519/jospt.2022.10761. Epub 2021 Nov 15. PubMed 34775831 ↗
  • Kamper SJ, Apeldoorn AT, Chiarotto A, Smeets RJ, Ostelo RW, Guzman J, van Tulder MW. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. BMJ. 2015 Feb 18;350:h444. doi: 10.1136/bmj.h444. PubMed 25694111 ↗
  • Jack K, McLean SM, Moffett JK, Gardiner E. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. Man Ther. 2010 Jun;15(3):220-8. doi: 10.1016/j.math.2009.12.004. Epub 2010 Feb 16. PubMed 20163979 ↗
  • Marras WS, Ferguson SA, Gupta P, Bose S, Parnianpour M, Kim JY, Crowell RR. The quantification of low back disorder using motion measures. Methodology and validation. Spine (Phila Pa 1976). 1999 Oct 15;24(20):2091-100. doi: 10.1097/00007632-199910150-00005. PubMed 10543004 ↗
  • Quirk DA, Chung J, Schiller G, Cherin JM, Arens P, Sherman DA, Zeligson ER, Dalton DM, Awad LN, Walsh CJ. Reducing Back Exertion and Improving Confidence of Individuals with Low Back Pain with a Back Exosuit: A Feasibility Study for Use in BACPAC. Pain Med. 2023 Aug 4;24(Suppl 1):S175-S186. doi: 10.1093/pm/pnad003. PubMed 36794907 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified IPD will be made available to other researchers in BACPAC.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will be made available upon publication of the study. It will remain available thereafter on https://healdata.org.

Access criteria: Members of BACPAC can access study data in the HEAL Initiative Data Repository using permalink: https://healdata.org/portal/discovery/HDP00349/

Data sharing details ↗ · healdata.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in May 2025, 13 months.

Results were first posted in Sep 2026, 1 year 4 months after primary completion.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 13 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Feb 21, 2023
StartActual
Mar 15, 2024
Primary completionActual
May 10, 2025
CompletionActual
May 10, 2025
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Primary outcomes
7 edited, 1 added, 5 removed
What changed in the outcomes
  • EditedChange in Suit Usability measuredMeasured by Quebec User Evaluation of Satisfaction withWith Assistive technologyTechnology (QUEST surveySurvey 2.0)Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • EditedChange in Suit Safety measuredMeasured by patientPatient-reported painPainTime frame: Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment)
  • EditedChange in SuitSuit Effect & Safety measuredMeasured by patient reported body discomfortPerceived Task DiscomfortTime frame: Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment) → Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • EditedChange in Suit Effect & Safety measuredMeasured by Perceived Task DiscomfortEffortTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • EditedChange in Suit Effect measuredMeasured by Concern of MovementTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • EditedChange inFunctional Suit Effect measuredMeasured by Perceived task effortEndurance Lifting TaskTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • EditedChange in Functional Suit effect measuredEffect Measured by peak deadlift pull forcePeak Deadlift Pull ForceTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • AddedFailure Percentage Level 6Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • RemovedChange in Biomechanical Suit Effect measured by Trunk range of motionTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • RemovedChange in Biomechanical Suit Effect measured by Trunk velocityTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • RemovedChange in Biomechanical Suit Effect measured by trunk coordinationTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • RemovedChange in Functional Suit Effect measured by peak dynamic lifting forceTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • RemovedChange in Functional Suit Effect measured by endurance lifting taskTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
Sep 30, 2026
Documents
Secondary outcomes
2 edited, 19 removed
What changed in the outcomes
  • EditedChange in Pain measuredMeasured by Numerical rating scaleRating Scale of painPain (worstWorst in lastLast 24 hoursHours)Time frame: Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment), and follow-up post discharge (up to 13 weeks post time 0) → Pre Every Visit including baseline (time 0), all follow-up visits
  • EditedChange in Patient-reported Disability score measuredScore Measured by the modifiedModified Oswestry Disability Questionnaire (MDQ)Time frame: Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment), and follow-up post discharge (up to 13 weeks post time 0) → Pre Every Visit including baseline (time 0)
  • Removedother outcomeChange in Trunk Biomechanics: peak trunk range of motionTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • Removedother outcomeChange in Trunk Biomechanics: peak trunk velocityTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • Removedother outcomeChange in Trunk Biomechanics: trunk coordinationTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • Removedother outcomeChange in Physical Function: walking speed with 10 meter walk testTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • Removedother outcomeChange in Physical Function: 5x sit to standTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • Removedother outcomeChange in Physical Function: Functional reachTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
  • Removedother outcomeChange in patient-reported pain symptoms: BACPAC minimum pain inventoryTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in Patient-reported physical function: Patient specific functional scale (PSFS)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient-reported pain catastrophizing: Pain catastrophizing scale (PCS-6)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in Patient-reported anxiety symptoms: Generalized anxiety disorder 2-item scale (GAD-2)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient reported substance use: Tobacco, Alcohol, Prescription medication and other substance use Screening tool (TAPS-1 tool)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient-reported pain interference: Patient-reported outcomes measurement information system - pain interference (PROMIS - pain interference)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient reported physical function: PROMIS - physical functionTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient-reported sleep quality: PROMIS- sleep disturbanceTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient depression scores: PROMIS - depressionTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient anxiety level: PROMIS - anxietyTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in patient kinesiophobia: Optimal screening for prediction of referral and outcome cohort yellow flag assessment tool (OSPRO-YF assessment tool).Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in reported pain: Pain, Enjoyment of life and General activity (PEG) ScaleTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
  • Removedother outcomeChange in reported disability: Pain, Enjoyment of life and general activity (PEG) ScaleTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    Primary outcomes 7 edited, 1 added, 5 removed
    What changed in the outcomes
    • EditedChange in Suit Usability measuredMeasured by Quebec User Evaluation of Satisfaction withWith Assistive technologyTechnology (QUEST surveySurvey 2.0)Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • EditedChange in Suit Safety measuredMeasured by patientPatient-reported painPainTime frame: Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment)
    • EditedChange in SuitSuit Effect & Safety measuredMeasured by patient reported body discomfortPerceived Task DiscomfortTime frame: Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment) → Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • EditedChange in Suit Effect & Safety measuredMeasured by Perceived Task DiscomfortEffortTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • EditedChange in Suit Effect measuredMeasured by Concern of MovementTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • EditedChange inFunctional Suit Effect measuredMeasured by Perceived task effortEndurance Lifting TaskTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • EditedChange in Functional Suit effect measuredEffect Measured by peak deadlift pull forcePeak Deadlift Pull ForceTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • AddedFailure Percentage Level 6Time frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • RemovedChange in Biomechanical Suit Effect measured by Trunk range of motionTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • RemovedChange in Biomechanical Suit Effect measured by Trunk velocityTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • RemovedChange in Biomechanical Suit Effect measured by trunk coordinationTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • RemovedChange in Functional Suit Effect measured by peak dynamic lifting forceTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • RemovedChange in Functional Suit Effect measured by endurance lifting taskTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    Secondary outcomes 2 edited, 19 removed
    What changed in the outcomes
    • EditedChange in Pain measuredMeasured by Numerical rating scaleRating Scale of painPain (worstWorst in lastLast 24 hoursHours)Time frame: Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment), and follow-up post discharge (up to 13 weeks post time 0) → Pre Every Visit including baseline (time 0), all follow-up visits
    • EditedChange in Patient-reported Disability score measuredScore Measured by the modifiedModified Oswestry Disability Questionnaire (MDQ)Time frame: Pre and Post Every Visit including baseline (time 0), all follow-up visits (up to 8 weeks of treatment), and follow-up post discharge (up to 13 weeks post time 0) → Pre Every Visit including baseline (time 0)
    • Removedother outcomeChange in Trunk Biomechanics: peak trunk range of motionTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • Removedother outcomeChange in Trunk Biomechanics: peak trunk velocityTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • Removedother outcomeChange in Trunk Biomechanics: trunk coordinationTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • Removedother outcomeChange in Physical Function: walking speed with 10 meter walk testTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • Removedother outcomeChange in Physical Function: 5x sit to standTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • Removedother outcomeChange in Physical Function: Functional reachTime frame: Measured periodically (at visits 1, 3, 6, 9, 12) between baseline (time 0) and 6-8 weeks of treatment.
    • Removedother outcomeChange in patient-reported pain symptoms: BACPAC minimum pain inventoryTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in Patient-reported physical function: Patient specific functional scale (PSFS)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient-reported pain catastrophizing: Pain catastrophizing scale (PCS-6)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in Patient-reported anxiety symptoms: Generalized anxiety disorder 2-item scale (GAD-2)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient reported substance use: Tobacco, Alcohol, Prescription medication and other substance use Screening tool (TAPS-1 tool)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient-reported pain interference: Patient-reported outcomes measurement information system - pain interference (PROMIS - pain interference)Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient reported physical function: PROMIS - physical functionTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient-reported sleep quality: PROMIS- sleep disturbanceTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient depression scores: PROMIS - depressionTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient anxiety level: PROMIS - anxietyTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in patient kinesiophobia: Optimal screening for prediction of referral and outcome cohort yellow flag assessment tool (OSPRO-YF assessment tool).Time frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in reported pain: Pain, Enjoyment of life and General activity (PEG) ScaleTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    • Removedother outcomeChange in reported disability: Pain, Enjoyment of life and general activity (PEG) ScaleTime frame: Baseline (time 0), all follow-up visits (up to 8 weeks of treatment) and post-discharge follow-up (up to 13 months from time 0)
    + 4 other changes: index terms, verification date, responsible party and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05736393
Responsible party
Lou Awad, PT, DPT, PhD (Principal investigator, Boston University Charles River Campus) — Principal investigator
First posted
Feb 21, 2023
Start date
Mar 15, 2024
Primary completion
May 10, 2025
Completion
May 10, 2025
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Conor Walsh, PhD
principal investigator · Harvard University
Lou N. Awad, PhD,DPT
principal investigator · Boston University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion